JOUNCE THERAPEUTICS INC (JNCE)       1.19  +0.06 (+5.31%)

1.19  +0.06 (+5.31%)

US4811161011 - Common Stock - After market: 1.2 +0.01 (+0.84%)


Fundamental Rating

2

Taking everything into account, JNCE scores 2 out of 10 in our fundamental rating. JNCE was compared to 639 industry peers in the Biotechnology industry. Both the profitability and financial health of JNCE have multiple concerns. While showing a medium growth rate, JNCE is valued expensive at the moment.

Note: JNCE has only limited data available, so a full analysis was not possible, which makes the total rating unfair.




Profitability

Profitability Rating

0

JNCE has a very weak Piotroski-F score of 2.00. This is an indication of health and profitability issues for JNCE.

VS Industry

Valuation

Valuation Rating

3

When comparing the current price to the book value of JNCE, it is valued rather cheaply. It is trading at 0.48 times its book value.
Compared to an average industry price book ratio of 1.87, JNCE is valued rather cheaply. On top of this, JNCE is cheaper than 86% of the companies listed in the same industry.

The Price/Earnings Ratio is negative for JNCE. In the last year negative earnings were reported.
Also next year JNCE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
VS Industry

Price/Book (0.48) VS Industry: 86% outperformed.

464.05
0.07

Growth

Growth Rating

4

JNCE is expected to show a strong growth in Revenue. In the coming 5 years, the Revenue will grow by 24.56% yearly.
The Revenue growth is accelerating: in the next 5 years the growth will be better than in the last years.
JNCE is expected to show a small growth in Earnings Per Share. In the coming 5 years, the EPS will grow by 6.51% yearly.

JNCE shows a decrease in Revenue. Measured over the last 5 years, the Revenue has been decreasing by -6.27% yearly.
The earnings per share for JNCE have decreased strongly by -556.41% in the last year.
The Revenue for JNCE has decreased by -100.00% in the past year. This is quite bad

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPSN/A N/A -556.41% -32.21% -10.14% -4.48% 6.51%
Revenue-6.27% -25.55% -100% -80.88% -51.66% -68.3% 24.56%

Health

Health Rating

3

JNCE has a Current Ratio of 6.42. This indicates that JNCE is financially healthy and has no problem in meeting its short term obligations.
JNCE has a Quick Ratio of 6.42. This indicates that JNCE is financially healthy and has no problem in meeting its short term obligations.
The Current Ratio is in line with the industry averages, which is at 6.21.
JNCE has a Quick Ratio comparable to the industry average, which is at 6.11.

The Debt to Equity ratio of JNCE is in line with the industry averages.
Based on the Altman-Z score of -3.64, we must say that JNCE is in the distress zone and has some risk of bankruptcy.
When comparing the Altman-Z score of JNCE to the average industry Altman-Z score of -0.13, JNCE is less financially healthy than its industry peers.
JNCE has a very weak Piotroski-F score of 2.00. This is an indication of health and profitability issues for JNCE.
VS Industry

Debt/Equity (0) VS Industry: 42% outperformed.

15.37
0.00

Quick Ratio (6.42) VS Industry: 52% outperformed.

0.04
84.53

Current Ratio (6.42) VS Industry: 52% outperformed.

0.08
85.09

Altman-Z (-3.64) VS Industry: 31% outperformed.

-94.22
622.88

Dividend

Dividend Rating

0

JNCE does not give a dividend.

JOUNCE THERAPEUTICS INC1.19

NASDAQ:JNCE (1/27/2023, 7:17:20 PM)+0.06 (+5.31%)

After market: 1.2 +0.01 (+0.84%)

Chartmill FA Rating
GICS Sector Health Care
GICS IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry Biotechnology
Earnings (Last) 11-10 2022-11-10/bmo Earnings (Next) 02-28 2023-02-28
Inst Owners 79.21% Inst Owner Change -0.67%
Ins Owners 0.98% Ins Owner Change -12.82%
Market Cap 61.52M Analysts 80
Price Target 6.12 (414.29%)

Dividend
Dividend Yield N/A Dividend Growth N/A
DP N/A Ex-Date N/A

Surprises & Revisions
EPS beat(2) 2 Avg EPS beat(2) 6.81%
Min EPS beat(2) 5.77% Max EPS beat(2) 7.85%
EPS beat(4) 2 Avg EPS beat(4) -22.83%
Min EPS beat(4) -82.18% Max EPS beat(4) 7.85%
Revenue beat(2) N/A Avg Revenue beat(2) -100%
Min Revenue beat(2) -100% Max Revenue beat(2) -100%
Revenue beat(4) N/A Avg Revenue beat(4) -100%
Min Revenue beat(4) -100% Max Revenue beat(4) -100%
PT rev (1m) -3.23% EPS NQ rev (1m) 0%
EPS NY rev (1m) 0% Revenue NQ rev (1m) 0%
Revenue NY rev (1m) 0%

Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.48
P/tB 0.48
EV/EBITDA N/A
EPS(TTM) -2.56 EY N/A
EPS(NY) -2.23 Fwd EY N/A
FCF(TTM) -2.27 FCFY N/A
OCF(TTM) -2.25 OCFY N/A
SpS N/A BVpS 2.5
TBVpS 2.5 PEG (NY) N/A
PEG (5Y) N/A

Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM N/A
GM N/A
ROICexgc(3y) N/A ROICexcg growth 3Y N/A
ROICexcg growth 5Y N/A ROICexc(3y) N/A
ROICexc growth 3Y N/A ROICexc growth 5Y N/A
OM growth 3Y N/A OM growth 5Y N/A
PM growth 3Y N/A PM growth 5Y N/A
GM growth 3Y N/A GM growth 5Y N/A
F-Score 2 Asset Turnover N/A

Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 35.93%
Profit Quality N/A
Current Ratio 6.42
Quick Ratio 6.42
Altman-Z -3.64
F-Score 2 WACC 9.04%
ROIC/WACC N/A Cap/Depr(3y) 13.93%
Cap/Depr(5y) 84.36% Profit Quality(3y) N/A
Profit Quality(5y) N/A

Growth
EPS 1Y -556.41% EPS 3Y N/A
EPS 5Y N/A EPS growth Q2Q -1.69%
EPS Next Y -32.21% EPS Next 2Y -10.14%
EPS Next 3Y -4.48% EPS Next 5Y 6.51%
Revenue growth 1Y -100% Revenue growth 3Y -25.55%
Revenue growth 5Y -6.27% Revenue growth Q2Q N/A
Revenue Next Year -80.88% Revenue Next 2Y -51.66%
Revenue Next 3Y -68.3% Revenue Next 5Y 24.56%
EBIT growth 1Y -423.27% EBIT growth 3Y N/A
EBIT growth 5Y N/A EBIT Next Year N/A
EBIT Next 3Y N/A EBIT Next 5Y N/A
FCF growth 1Y -36.52% FCF growth 3Y N/A
FCF growth 5Y N/A OCF growth 1Y -35.72%
OCF growth 3Y N/A OCF growth 5Y N/A

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA